therapeutic melatonin
Phase 2Small molecule
Radiation Therapy Oncology Grouptherapeutic melatonin is one of 4 small molecule programs targeting Sleep Disturbance. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
3 competitors in Sleep Disturbance
#DrugCompanyPhaseTrials
1Belsomra
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Adhansia Xr
NovartisPhase 2
therapeutic melatonin
Radiation Therapy Oncology GroupPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for therapeutic melatonin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details